1. Home
  2. ANGI vs MYGN Comparison

ANGI vs MYGN Comparison

Compare ANGI & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Angi Inc.

ANGI

Angi Inc.

HOLD

Current Price

$13.98

Market Cap

551.9M

ML Signal

HOLD

Logo Myriad Genetics Inc.

MYGN

Myriad Genetics Inc.

HOLD

Current Price

$6.52

Market Cap

625.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANGI
MYGN
Founded
1995
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Advertising
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
551.9M
625.5M
IPO Year
2017
1995

Fundamental Metrics

Financial Performance
Metric
ANGI
MYGN
Price
$13.98
$6.52
Analyst Decision
Buy
Buy
Analyst Count
6
12
Target Price
$18.20
$11.82
AVG Volume (30 Days)
920.8K
914.1K
Earning Date
02-10-2026
02-23-2026
Dividend Yield
N/A
N/A
EPS Growth
13.43
N/A
EPS
0.72
N/A
Revenue
$1,057,636,000.00
$825,300,000.00
Revenue This Year
N/A
$0.08
Revenue Next Year
$3.41
$5.28
P/E Ratio
$19.62
N/A
Revenue Growth
N/A
0.21
52 Week Low
$10.25
$3.76
52 Week High
$20.70
$15.47

Technical Indicators

Market Signals
Indicator
ANGI
MYGN
Relative Strength Index (RSI) 63.22 45.83
Support Level $12.23 $6.09
Resistance Level $14.58 $6.85
Average True Range (ATR) 0.57 0.25
MACD 0.11 0.03
Stochastic Oscillator 74.78 54.66

Price Performance

Historical Comparison
ANGI
MYGN

About ANGI Angi Inc.

Angi Inc connects quality home service professionals with consumers across different categories, from repairing and remodeling to cleaning and landscaping. It operates through brands like Angi, HomeAdvisor, and Handy. The company has three operating segments, namely, Ads and Leads, Services, and International (Europe and Canada). A majority of its revenue is generated from the Ads and Leads segment, which provides professionals the capability to engage with potential customers, including quoting and invoicing services, and provides consumers with tools and resources to help them find professionals nationwide for home repair, maintenance, and improvement projects. Geographically, the company derives its key revenue from the United States and also has a presence in other countries.

About MYGN Myriad Genetics Inc.

Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.

Share on Social Networks: